research report · LCTX

Lineage Cell Therapeutics, Inc.

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 13, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Nov 12, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Deteriorating

worse on balance: sales, margins, cash or competitive position

financial resilience

Adequate

funded for about two years, partly by routine borrowing or new issuance

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Lineage is weaker than a year ago on its operating loss and cash burn, and its economics still rest on a Roche decision about OpRegen that the filings do not show. The quarter's $4.2M net income comes from an $11.9M non-cash warrant gain. The operating loss was $7.3M, against $3.8M a year earlier. Cash used in operations eased to about $5.6M, its lowest quarter of 2026. Management projects that $45.2M of cash and securities funds the plan "into Q2 2028", one quarter earlier than before, after about $4.3M was paid on day one for the Huntington's disease program HUNT1. Beyond that date the plan depends on share sales or warrant exercises.

what changed this quarter

  • Revenue fell 61% to $1.43M from $3.68M. Roche work fell $1.2M and WDI work $1.0M, both on fewer services.
  • Research and development (R&D) rose 17% to $3.8M, primarily on preclinical/undisclosed programs and ReSonance; OpRegen fell $0.6M. General and administrative costs rose 18% to $4.9M on personnel and stock compensation.
  • Net income attributable to Lineage was $4.2M, against a $29.8M loss a year earlier; the swing is the warrant remeasurement.
  • Cash and securities fell to $45.2M from $50.8M at June 30. No shares were sold in the quarter.
  • On November 12, Lineage bought NeuroAirmid and rights to HUNT1, which is in a Phase 1b/2a study at UC Irvine.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • The quarter's profit is a warrant mark; the loss is up on the year even as burn eased
  • HUNT1 is cheap to enter but brings a long tail of claims, and data Lineage does not control
  • Revenue is the run-off of Roche's 2022 payment; Roche's OpRegen decision remains undisclosed

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what LCTX files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on LCTX say?” Add Viridis to Claude, or to ChatGPT.